|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SPRYD3 |
Gene summary for SPRYD3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SPRYD3 | Gene ID | 84926 |
| Gene name | SPRY domain containing 3 | |
| Gene Alias | SPRYD3 | |
| Cytomap | 12q13.13 | |
| Gene Type | protein-coding | GO ID | GO:0006996 | UniProtAcc | A0A024RAX4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84926 | SPRYD3 | LZE4T | Human | Esophagus | ESCC | 5.54e-05 | 1.65e-01 | 0.0811 |
| 84926 | SPRYD3 | LZE8T | Human | Esophagus | ESCC | 3.76e-06 | 2.18e-01 | 0.067 |
| 84926 | SPRYD3 | LZE24T | Human | Esophagus | ESCC | 3.64e-14 | 4.04e-01 | 0.0596 |
| 84926 | SPRYD3 | P1T-E | Human | Esophagus | ESCC | 4.44e-04 | 2.91e-01 | 0.0875 |
| 84926 | SPRYD3 | P2T-E | Human | Esophagus | ESCC | 5.27e-28 | 4.65e-01 | 0.1177 |
| 84926 | SPRYD3 | P4T-E | Human | Esophagus | ESCC | 3.83e-07 | 1.39e-01 | 0.1323 |
| 84926 | SPRYD3 | P5T-E | Human | Esophagus | ESCC | 8.46e-10 | 2.16e-01 | 0.1327 |
| 84926 | SPRYD3 | P8T-E | Human | Esophagus | ESCC | 4.70e-17 | 3.36e-01 | 0.0889 |
| 84926 | SPRYD3 | P9T-E | Human | Esophagus | ESCC | 6.67e-04 | 7.83e-02 | 0.1131 |
| 84926 | SPRYD3 | P10T-E | Human | Esophagus | ESCC | 2.26e-05 | 1.09e-01 | 0.116 |
| 84926 | SPRYD3 | P11T-E | Human | Esophagus | ESCC | 3.81e-16 | 5.84e-01 | 0.1426 |
| 84926 | SPRYD3 | P12T-E | Human | Esophagus | ESCC | 7.68e-17 | 2.22e-01 | 0.1122 |
| 84926 | SPRYD3 | P15T-E | Human | Esophagus | ESCC | 3.70e-13 | 2.69e-01 | 0.1149 |
| 84926 | SPRYD3 | P16T-E | Human | Esophagus | ESCC | 8.46e-18 | 3.00e-01 | 0.1153 |
| 84926 | SPRYD3 | P17T-E | Human | Esophagus | ESCC | 1.55e-11 | 4.52e-01 | 0.1278 |
| 84926 | SPRYD3 | P19T-E | Human | Esophagus | ESCC | 1.64e-15 | 8.83e-01 | 0.1662 |
| 84926 | SPRYD3 | P20T-E | Human | Esophagus | ESCC | 6.74e-21 | 4.71e-01 | 0.1124 |
| 84926 | SPRYD3 | P21T-E | Human | Esophagus | ESCC | 1.95e-30 | 6.21e-01 | 0.1617 |
| 84926 | SPRYD3 | P22T-E | Human | Esophagus | ESCC | 2.66e-10 | 2.56e-01 | 0.1236 |
| 84926 | SPRYD3 | P23T-E | Human | Esophagus | ESCC | 5.60e-17 | 4.34e-01 | 0.108 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SPRYD3 | SNV | Missense_Mutation | c.826C>A | p.Leu276Met | p.L276M | Q8NCJ5 | protein_coding | deleterious(0.03) | probably_damaging(0.94) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD | |
| SPRYD3 | SNV | Missense_Mutation | c.649N>A | p.Glu217Lys | p.E217K | Q8NCJ5 | protein_coding | deleterious(0.01) | benign(0.017) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SPRYD3 | SNV | Missense_Mutation | novel | c.25T>G | p.Phe9Val | p.F9V | Q8NCJ5 | protein_coding | tolerated_low_confidence(0.13) | benign(0.001) | TCGA-C8-A12X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SPRYD3 | SNV | Missense_Mutation | novel | c.25N>G | p.Phe9Val | p.F9V | Q8NCJ5 | protein_coding | tolerated_low_confidence(0.13) | benign(0.001) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
| SPRYD3 | SNV | Missense_Mutation | novel | c.448N>A | p.Glu150Lys | p.E150K | Q8NCJ5 | protein_coding | tolerated(0.81) | benign(0.006) | TCGA-LQ-A4E4-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | PD |
| SPRYD3 | insertion | Nonsense_Mutation | novel | c.123_124insGGAGTAGGGTGAGGTGACCTTAAGT | p.Tyr42GlyfsTer4 | p.Y42Gfs*4 | Q8NCJ5 | protein_coding | TCGA-BH-A0BV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | ||
| SPRYD3 | SNV | Missense_Mutation | rs758769095 | c.398N>A | p.Arg133His | p.R133H | Q8NCJ5 | protein_coding | tolerated(0.1) | possibly_damaging(0.494) | TCGA-EA-A4BA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| SPRYD3 | SNV | Missense_Mutation | rs776074767 | c.215N>A | p.Arg72Gln | p.R72Q | Q8NCJ5 | protein_coding | tolerated(0.38) | benign(0.012) | TCGA-CK-5916-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| SPRYD3 | SNV | Missense_Mutation | c.898N>A | p.Ala300Thr | p.A300T | Q8NCJ5 | protein_coding | deleterious(0.02) | possibly_damaging(0.836) | TCGA-EI-6507-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| SPRYD3 | SNV | Missense_Mutation | novel | c.1033N>A | p.Asp345Asn | p.D345N | Q8NCJ5 | protein_coding | deleterious(0.05) | possibly_damaging(0.63) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |